A Japanese Phase I Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 May 2010 Official Title amended, actual initiation date (JAn 2010) added, Genzyme corporation Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.